Neurogene (NASDAQ:NGNE) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Neurogene (NASDAQ:NGNE - Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $55.00 price objective on the stock.

NGNE has been the subject of several other research reports. BMO Capital Markets reduced their price objective on shares of Neurogene from $65.00 to $60.00 and set an "outperform" rating for the company in a research report on Tuesday, November 12th. Stifel Nicolaus increased their price objective on shares of Neurogene from $44.00 to $60.00 and gave the stock a "buy" rating in a research report on Tuesday, November 12th. Leerink Partners upped their price target on Neurogene from $45.00 to $72.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 12th. Finally, Robert W. Baird raised their price objective on Neurogene from $54.00 to $72.00 and gave the company an "outperform" rating in a research note on Tuesday, November 12th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $63.33.

Neurogene Trading Down 11.8 %

Shares of NGNE traded down $2.34 during trading hours on Tuesday, hitting $17.48. 942,584 shares of the stock were exchanged, compared to its average volume of 153,039. Neurogene has a fifty-two week low of $12.49 and a fifty-two week high of $74.49. The business has a 50-day moving average of $46.80 and a 200-day moving average of $40.09.

Institutional Trading of Neurogene

Large investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new stake in Neurogene during the first quarter worth about $120,000. Vanguard Group Inc. boosted its stake in Neurogene by 906.5% in the first quarter. Vanguard Group Inc. now owns 507,483 shares of the company's stock worth $25,831,000 after buying an additional 457,062 shares in the last quarter. Baker BROS. Advisors LP boosted its stake in Neurogene by 0.6% in the first quarter. Baker BROS. Advisors LP now owns 456,015 shares of the company's stock worth $23,211,000 after buying an additional 2,499 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Neurogene during the second quarter valued at approximately $1,107,000. Finally, Rhumbline Advisers purchased a new position in shares of Neurogene during the second quarter worth approximately $491,000. Institutional investors own 52.37% of the company's stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.